

# Joint DIA/ICOS Cardio-Oncology Conference: *Cardiac Toxicity Resulting From Cancer Chemotherapy*

Event #14108

9-10 October 2014

Dorint Hotel Don Giovanni, Prague, Czech Republic



## Programme Co-Chairs:

**Boaz Mendzelevski**

Vice President of Cardiology, Bioclinica Inc, UK

**Daniel J. Lenihan**

President, International CardioOncology Society North America (ICOSNA), Director of Cardiovascular Clinical Research Programs, Vanderbilt University, Vanderbilt University, USA

## Programme Committee

**Giuseppe Curigliano, MD**

President, International CardioOncology Society (ICOS) Europe, Senior Deputy Director, European Institute of Oncology, Italy

**Krishna Prasad, MD**

Group Manager (Interim) /Expert Assessor, MHRA; Consultant Cardiologist, St Thomas' Hospital, UK

## Continuing Education

DIA meetings are generally approved by the SwAPP (Swiss Association of Pharmaceutical Professionals), Commission for Professional Development (CPD) and SGPM (Swiss Society of Pharmaceutical Medicine) and will be honoured with credits for pharmaceutical medicine. All participants are eligible for these credits and certificates are available on request from the registration desk.

## Overview

There is a tremendous amount of mechanistic overlap between targeted cancer therapy and cardiovascular tissues. Important drugs that may be active on cancer are increasingly likely to have significant collateral effects on cardiovascular structures. Understanding the underlying mechanisms and how to detect these problems early and manage them effectively can allow a critical drug for cancer efficacy to continue to develop as a clinical therapy. Additionally, tailoring the pharmacology of a potential cancer therapeutic based on known mechanistic insights is an essential area of preclinical development. Furthermore, enhancing interactions between cardiology and oncology at all levels of clinical trials allows for optimal patient outcomes.

## Key Topics

- Best methods of cardiotoxicity detection during early phase clinical trials
- Best management approaches to protecting cardiac tissues during aggressive cancer therapy
- Known and theorised mechanistic actions of developing cancer therapy to allow cardioprotection
- Effective communication between drug developers and prescribers
- Optimal patient care between cardiology and oncology

## Who Will Attend

- Cardiology, oncology and primary care physicians, nurse practitioners, and other allied providers
- Drug development and clinical research managers and associates
- Pharmacovigilance, drug safety and drug surveillance personnel
- Pharmaceutical physicians and medical directors
- Safety pharmacology and non-clinical scientists
- Clinical pharmacology scientists
- Regulatory affairs officers
- Biostatisticians
- Data managers
- Outsourcing and marketing managers

The audience will include clinical research and industry experts including drug development scientists, regulatory officials and academicians managing patients undergoing cancer therapy.

For more information please contact [Sharon.Evans@diaeurope.org](mailto:Sharon.Evans@diaeurope.org) | +41 61 225 51 44

## *Exhibition Opportunities Available!*

Showcase your product or service to a truly global audience of qualified professionals, from entry level to expert, in the pharmaceutical, biotechnology, devices and related healthcare industries, government, academia and healthcare delivery.

For more information on exhibiting space and facilities, please contact Roxann Schumacher at DIA on +41 61 225 51 38 or email: [roxann.schumacher@diaeurope.org](mailto:roxann.schumacher@diaeurope.org)

## 09 OCTOBER 2014

08:00 REGISTRATION AND WELCOME COFFEE

08:50 WELCOME AND OPENING COMMENTS

Boaz Mendzelevski, Vice President of Cardiology, Bioclinica Inc, UK

09:00 Session 1

**PRECLINICAL MODELS FOR ENSURING CARDIAC SAFETY**

Co-Moderators:

**Boaz Mendzelevski**, Vice President of Cardiology, Bioclinica Inc, UK  
**Krishna Prasad, MD****Group Manager** (Interim) /Expert Assessor, MHRA; Consultant Cardiologist, St Thomas' Hospital, UK

In this session we will describe the scope of toxicities and how these are documented.

**Cardiac Safety During Cancer Therapy: Clinical relevance and the scope of the problem**

Daniel J. Lenihan, President, International CardiOncology Society North America (ICOSNA), Director of Cardiovascular Clinical Research Programs, Vanderbilt University, Vanderbilt University, USA

**Preclinical Monitoring and Safety: Receptor cross-targets in cancer and cardiac tissue**

Speaker invited

**How Do We Detect Anticipated and Unanticipated Cardiac Toxicities in Early Phase Studies?**

Jakob Dupont, Vice President, Clinical Development; Oncomed, USA

**Panel Discussion:** All Speakers and Moderators

10:30 COFFEE BREAK

11:00 Session 2

**DIRECT MYOCARDIAL TOXICITY, CARDIAC BIOMARKERS, AND DETECTING HEART FAILURE**

Co-Moderators:

**Alexander Lyon**, Senior Lecturer and Consultant Cardiologist, Royal Brompton Hospital, London, UK**Daniela Cardinale**, Vice-President, International CardiOncology Society (ICOS) Europe and Asia; Director, Cardio-Oncology Unit, European Institute of Oncology, Italy

In this session we will describe direct myocardial toxicity and detection in the clinical arena.

**Cancer Drug Development: Many potential targets can have cardiotoxicity**

Alexander Lyon, Senior Lecturer and Consultant Cardiologist, Royal Brompton Hospital, London, UK

**Role of Troponin and Natriuretic Peptides in Predicting and Preventing Cardiac Events in Cancer Patients**

Daniela Cardinale, Vice-President, International CardiOncology Society (ICOS) Europe and Asia; Director, Cardio-Oncology Unit, European Institute of Oncology, Italy

**What Cut-Off for B-type Natriuretic Peptide (BNP) Should We Have to Identify Risk for Heart Failure?**

Kenneth McDonald, Chronic Cardiovascular Disease Management Unit, St Vincent's Healthcare Group, Ireland

**Panel Discussion:** All Speakers and Moderators

12:30 LUNCH

13:30 Session 3

**CARDIAC SAFETY IMAGING IN CLINICAL RESEARCH**

Co-Moderators:

**Okan Ekinci**, Global Director, Cardiology, Siemens Healthcare, Germany**Daniel Rodriguez Muñoz**, Department of Cardiology, Ramón y Cajal University Hospital, Spain

In this session the latest considerations for clinical imaging and cardiac safety will be highlighted.

**What are the Expectations for Optimal Echo Imaging?**

Daniel Rodriguez Muñoz, Department of Cardiology, Ramón y Cajal University Hospital, Spain

**How can MRI be Utilised Most Effectively?**

Okan Ekinci, Global Director, Cardiology, Siemens Healthcare, Germany

**Are Nuclear Techniques Really Obsolete?**

Otto Lang, Department of Nuclear Medicine, Third Faculty of Medicine, Charles University, Czech Republic

**Panel Discussion:** All Speakers and Moderators

15:00 COFFEE BREAK

15:30 Session 4

**CELLULAR SIGNALING AND LEFT VENTRICULAR DYSFUNCTION: TOXICITY MITIGATION OR THERAPEUTIC TREATMENT?**

Co-Moderators:

**Giuseppe Curigliano**, President, International CardiOncology Society (ICOS) Europe, Senior Deputy Director, European Institute of Oncology, Italy**Susan Dent**, President, International CardiOncology Society (ICOS) Canada, Medical Oncologist, Founder, Canadian Cardiac Oncology Network, Canada

In this session the concept of translational research informing clinical practice will be introduced.

**How does Cardiotoxicity Affect our Cancer Treatment Choices?**

Giuseppe Curigliano, President, International CardiOncology Society (ICOS) Europe, Senior Deputy Director, European Institute of Oncology, Italy

**Neuregulin: A classic ligand for myocardial protection?**

Tony Caggiano, Director of Translational Research, Acorda Therapeutics, USA

**Cardioprotection: Do we target the myocardium or the patient?**

Xavier Bosch, Hospital and Clinic, Barcelona, Spain

**Panel Discussion:** All Speakers and Moderators**Summary and Closing Comments**

Giuseppe Curigliano, President, International CardiOncology Society (ICOS) Europe, Senior Deputy Director, European Institute of Oncology, Italy

17:40 DRINKS RECEPTION

18:30 END OF DAY ONE

## DISCLOSURE

Unless otherwise disclosed, DIA Europe acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA Europe. Speakers and agenda are subject to change without notice. Recording of any DIA Europe information in any type of media is prohibited without prior written consent from DIA Europe.

## FRIDAY 10 OCTOBER 2014

08:00 REGISTRATION AND WELCOME COFFEE

09:00 Session 5

**HYPERTENSION: SAFETY REQUIREMENTS AND TREATMENT**

Co-Moderators:

**Ron Witteles**, Assistant Professor of Medicine, Stanford University Medical Center, USA**Giuseppe Curigliano**, President, International CardiOncology Society (ICOS) Europe, Senior Deputy Director, European Institute of Oncology, Italy

How is hypertension an important safety issue in Oncology Trials?

**Oncology Drug-Induced Hypertension: An Overview**

Boaz Mendzelevski, Vice President of Cardiology, Bioclinica Inc, UK

**How much of a Concern is there for HTN with Newer Targeted Cancer Therapy?**

Ron Witteles, Assistant Professor of Medicine, Stanford University Medical Center, USA

**Case Presentations: How do we actually manage HTN in cancer patients with ongoing therapy?**

Sebastian Szmit, Center of Postgraduate Medical Education; Secretary, ICOS Eastern Europe Branch, Poland

**Panel Discussion:** All Speakers and Moderators

10:30 COFFEE BREAK

11:00 Session 6

**ARTERIAL / VENOUS THROMBOTIC EVENTS**

Co-Moderators:

**Adam Torbicki**, Head, Department of Chest Medicine, Warsaw; President of Eastern European Branch ICOS, Poland**Giorgio Minotti, Professor**, University Campus Bio-Medica, Italy

In this session the complex interplay between thrombosis and anticoagulation in cancer patients will be described.

**Do We Have any Concerns about Arterial and Venous Thrombotic Events with Newer Agents?**

Giorgio Minotti, Professor, University Campus Bio-Medica, Italy

**How Do We Assess the Risk of Thrombosis?**

Aleš Linhart, First Medical Faculty, Charles University, Czech Republic

**What Is The Optimal Anticoagulation Strategy for Venous Thrombosis in Cancer Patients?**

Adam Torbicki, Head, Department of Chest Medicine, Warsaw; President, International CardiOncology Society (ICOS Eastern European), Poland

**Panel Discussion:** All Speakers and Moderators

12:30 LUNCH

14:00 Session 7

**BIOSIMILARS: WHAT MUST WE EXPECT? POINT/COUNTERPOINT**

Moderator invited

In the session the need to identify standards for biosimilar approval will be discussed.

**Industry Perspective on Biosimilars**

Speaker invited

**How Rigorous Should We Be to Establish Biosimilar Efficacy?**

Rodeina Challand, Executive Director, Biosimilars Development, Scientific Affairs, PRA International, UK

**Roadmap for Approving Generic or Biosimilar Antibodies**

Krishna Prasad, Group Manager (Interim) /Expert Assessor, MHRA; Consultant Cardiologist, St Thomas' Hospital, UK

**Panel Discussion:** All Speakers and Moderators

15:30 COFFEE BREAK

16:00 Session 8

**INTEGRATION AND COOPERATION-HOW DO WE ACHIEVE THIS?**

Co-Moderators:

**Susan Dent**, President, International CardiOncology Society (ICOS) Canada, Medical Oncologist, Founder, Canadian Cardiac Oncology Network, Canada**Daniel J. Lenihan**, President, International CardiOncology Society North America (ICOSNA), Director of Cardiovascular Clinical Research Programs, Vanderbilt University, Vanderbilt University, USA

In this session we will explore how to integrate cardiac safety into oncology research and practice.

**How Do We Organise and Deliver on Cooperation among Disciplines**

Speaker invited

**Cardiac Safety Assessment in Oncology Drug Development: Regulatory Involvement in International Collaborative Activities**

Colette Strnadova, Senior Scientific Advisor, Health Canada, Canada

**How Do We Best Interact on Patient Care: An Oncologist point of view**

Susan Dent, President, International CardiOncology Society (ICOS) Canada, Medical Oncologist, Founder, Canadian Cardiac Oncology Network, Canada

**Panel Discussion:** All Speakers and Moderators

17:40 WRAP UP AND END OF CONFERENCE

Daniel J. Lenihan and Boaz Mendzelevski

**About DIA**

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA's network creates unparalleled opportunities for exchange of knowledge and has the interdisciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation headquartered in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China.

For more information, visit [www.diahome.org](http://www.diahome.org) or call DIA Europe +41 61 225 51 51.

# REGISTRATION FORM

Joint DIA/ICOS Conference on Cardiac Toxicity Resulting From Cancer Chemotherapy

9-10 October 2014 | Dorint Hotel Don Giovanni, Prague, Czech Republic



ID #14108

## FEES

	Member*	Non-Member*
Industry	€ 1'400.00 <input type="checkbox"/>	€ 1'530.00 <input type="checkbox"/>
Academia/Charitable/Government/Non-profit (Full-time)	€ 700.00 <input type="checkbox"/>	€ 830.00 <input type="checkbox"/>
Join DIA now to qualify for the member rate	€ 130.00 <input type="checkbox"/>	

\* All fees will be subject to the local Czech VAT at 21%

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee.

Group discount/SME rates available. Special rates for students and patient representatives on offer, subject to availability – please contact DIA Europe for more information.

Registration fee includes: refreshments, lunches and meeting material.

Payment is due 30 days after registration and must be paid in full by commencement of the event.

**TOTAL AMOUNT DUE:** \_\_\_\_\_

## ATTENDEE DETAILS

Please complete in block capital letters or attach the attendee's business card here.

Prof  Dr  Ms  Mr

Last Name

First Name

Company

Job Title

Address

Postal Code  City

Country

Telephone

Fax

Email\*

\*(Required for confirmation)

DIA reserves the right to include your name and affiliation on the attendee list.

## PAYMENT METHODS

**Credit cards:** Payments by VISA, Mastercard or AMEX can be made by completing the details below. Please note that other types of credit card cannot be accepted.

Please charge my  VISA  MC  AMEX

Card N°

Exp. Date  /

Cardholder's Name

**Bank transfers:** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to "Account Holder: DIA." Please include your name, company, Event ID #14108 as well as the invoice number to ensure correct allocation of your payment.

Payments must be net of all charges and bank charges must be borne by the payer. **If you have not received your confirmation within five working days, please contact DIA Europe.**

By signing below, I confirm that I agree with DIA Europe's Terms and Conditions of booking. These are available from the office or on <http://www.diahome.org/EUTerms>

Date

Signature

## Cancellation Policy

All cancellations must be made in writing and be received at the DIA Europe office five working days prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) (Member/Non-member) € 100.00
- Tutorial cancellation € 50.00

If you do not cancel five working days prior to the event start date and do not attend, you will be responsible for the full registration fee. DIA Europe reserves the right to alter the venue and dates if necessary. If an event is cancelled or postponed, DIA Europe is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

## Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA Europe office of any such substitutions as soon as possible.

## Photography Policy

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA Europe in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.